8-K: Heron Therapeutics Q1 2026 Results: Acute Care Growth Strong

Heron Therapeutics announced first quarter 2026 financial results, reporting $34.7 million in net revenue and reaffirming full-year guidance, driven by significant growth in its Acute Care franchise.

Summary

• Heron Therapeutics reported first quarter 2026 net revenue of $34.7 million, a decrease of 10.8% compared to the same period in 2025.
• The Acute Care franchise showed strong year-over-year growth of 32.3%, with ZYNRELEF revenue up 27.3% to $10.2 million and APONVIE revenue up 50.2% to $3.4 million.
• The Oncology Supportive Care franchise revenue decreased by 26.3% to $21.1 million, primarily due to a decline in CINVANTI revenue by 20.2% and SUSTOL by 80.9%.
• The company reaffirmed its full-year 2026 guidance for net revenue between $173 million and $183 million, and Adjusted EBITDA between $10 million and $20 million.
• Heron ended the first quarter with $44.8 million in cash, cash equivalents, and short-term investments.
• A settlement was reached with Baxter Healthcare Corporation in the CINVANTI patent litigation, with the case dismissed on April 28, 2026.
• The company experienced typical first-quarter seasonality and weather-related disruptions but saw a recovery in February and March.
• Gross margin pressure is expected to normalize over the next two quarters as higher-cost CINVANTI inventory is worked through.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed-to-negative result due to the year-over-year revenue decline and shift to a net loss, despite positive growth in specific product lines and reaffirmed guidance.

Positives

• Acute Care franchise net revenue increased by 32.3% year-over-year.
• ZYNRELEF net revenue grew 27.3% to $10.2 million.
• APONVIE net revenue grew 50.2% to $3.4 million.
• ZYNRELEF demand units increased by 22% year-over-year.
• APONVIE demand units increased by 68% year-over-year.
• APONVIE gained P&T approval in 1,902 accounts.
• Settlement reached in CINVANTI patent litigation with Baxter Healthcare Corporation.
• Full-year 2026 net revenue guidance of $173-$183 million reaffirmed.
• Full-year 2026 Adjusted EBITDA guidance of $10-$20 million reaffirmed.

Negatives

• Total net revenue decreased by 10.8% to $34.7 million in Q1 2026 compared to Q1 2025.
• Oncology Supportive Care franchise revenue decreased by 26.3% to $21.1 million.
• CINVANTI net revenue decreased by 20.2% to $20.5 million.
• SUSTOL net revenue decreased by 80.9% to $0.6 million.
• Net loss from operations was $4.765 million in Q1 2026, compared to income from operations of $3.154 million in Q1 2025.
• Net loss for the quarter was $8.111 million, compared to net income of $2.635 million in Q1 2025.
• Adjusted EBITDA was a loss of $0.727 million in Q1 2026, compared to positive Adjusted EBITDA of $6.216 million in Q1 2025.
• Expected temporary gross margin pressure due to higher-cost CINVANTI inventory.

Risks

• Typical first-quarter seasonality and unusual weather-related disruption early in the quarter impacted performance.
• Temporary gross margin pressure is expected as the company works through higher-cost CINVANTI inventory over the next two quarters.
• The wind-down of SUSTOL by the end of 2026 will continue to impact Oncology Supportive Care revenue.
• Potential for future equity financings may be needed.
• Inability or delay in achieving profitability.
• Regulatory developments and policy changes in the U.S. and other jurisdictions.

Future Outlook

Heron Therapeutics reaffirmed its full-year 2026 guidance, projecting net revenue between $173 million and $183 million and Adjusted EBITDA between $10 million and $20 million. The company anticipates deferred elective procedures to return and commercial catalysts like IGNITE 2.0, unique J-Codes, and planned sales force expansion to drive growth. Temporary gross margin pressure is expected to normalize as higher-cost CINVANTI inventory is managed over the next two quarters.

Management Comments

• "Despite typical first-quarter seasonality and unusual weather-related disruption early in the quarter, we saw a clear recovery in February and March."
• "Our Acute Care franchise continues to perform with strong year-over-year growth, and we remain confident in our full-year framework as deferred elective procedures return and our commercial catalysts such as IGNITE 2.0, unique J-Codes, and planned sales force expansion for the Acute Care franchise continue to build through 2026."
• "As environmental conditions normalized, we saw momentum rebuild through February and exited March with improved trends."
• "We maintained disciplined cost management and expect temporary gross margin pressure to normalize as we work through higher-cost CINVANTI inventory over the next two quarters."

Industry Context

StockSavvy.ai notes that Heron Therapeutics' Q1 2026 results reflect the challenging seasonality often seen in the first quarter for pharmaceutical companies, compounded by external factors like weather. The strong performance of the Acute Care franchise, particularly ZYNRELEF and APONVIE, highlights the company's ability to drive growth in key therapeutic areas, while the decline in the Oncology Supportive Care franchise, specifically CINVANTI, indicates ongoing market dynamics and inventory management challenges. The reaffirmation of full-year guidance suggests management's confidence in overcoming near-term headwinds.

Comparison to Industry Standards

• Heron's Acute Care franchise growth of 32.3% in Q1 2026 is robust compared to the typical low-to-mid single-digit growth seen in many established pharmaceutical product lines.
• The year-over-year demand unit increase for ZYNRELEF (22%) and APONVIE (68%) suggests strong market penetration and adoption, potentially outpacing competitors in their respective niches.
• CINVANTI's maintained 25% market share in the NK1 CINV category indicates competitive positioning against other treatments like Emend (aprepitant) and other NK1 antagonists, despite the revenue decline.
• The company's net loss from operations and negative Adjusted EBITDA in Q1 2026, while concerning, is not uncommon for commercial-stage biotech companies investing heavily in sales, marketing, and product development, especially when facing inventory adjustments.

Legal Proceedings

• Settlement reached with Baxter Healthcare Corporation in CINVANTI patent litigation.
• U.S. District Court for the District of Delaware dismissed the pending litigation between Heron and Baxter Healthcare Corporation on April 28, 2026.

Stakeholder Impact

• Shareholders: Reaffirmed full-year guidance provides some certainty, but the year-over-year decline in revenue and shift to net loss may be concerning.
• Employees: Planned sales force expansion in Q3 2026 indicates continued investment in commercial capabilities.
• Creditors: Company ended the quarter with $44.8 million in cash, cash equivalents, and short-term investments, providing a buffer for operations.

Next Steps

• Continue to build momentum through 2026 with commercial catalysts.
• Recruitment underway to increase coverage and account depth across the portfolio for sales force expansion in Q3 2026.
• Active promotion of CINVANTI as part of the planned sales force expansion.
• Work through higher-cost CINVANTI inventory over the next two quarters to normalize gross margins.
• Receive 12-month stability data for the ZYNRELEF prefilled syringe (PFS) lifecycle program in Q1 2027.

Key Dates

Recommendation

The company's Q1 2026 results show a year-over-year decline in total revenue and a shift from profit to loss, which is a negative indicator. However, the strong growth in the Acute Care franchise (ZYNRELEF and APONVIE) and the reaffirmation of full-year guidance suggest underlying operational strengths and management confidence in future performance. The settlement of patent litigation is also a positive. Given the mixed results, a 'hold' recommendation is appropriate, pending further clarity on the normalization of gross margins and sustained growth in key products.

Keywords

Heron Therapeutics, 8-K, Financial Results, Q1 2026, Acute Care, Oncology Supportive Care, ZYNRELEF, APONVIE